PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29277797
OWN - NLM
STAT- In-Process
LR  - 20171226
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - First Clinical Data of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
      as Salvage Therapy for Peritoneal Metastatic Biliary Tract Cancer.
PG  - 373-378
AB  - BACKGROUND: Patients suffering from peritoneal metastasis of biliary tract cancer
      were treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).
      PATIENTS AND METHODS: This was a study carried out at a single institution,
      tertiary referral center certified for therapy of peritoneal disease.
      Retrospective data analysis was performed of prospective data for PIPAC with
      intra-peritoneal low-dose doxorubicin (1.5 mg/m(2)) and cisplatin (7.5 mg/m(2))
      delivered at intervals of 6 weeks. The outcome criteria were microscopic
      pathological response, survival, and adverse events [Common Terminology Criteria 
      of Adverse Events (v4.0)]. RESULTS: A total of 13 patients (male/female=8/5) with
      a mean age of 58 (range=37-75) years underwent 17 PIPAC procedures without
      intraoperative complications. The mean number of PIPAC applications was 1.3
      (range=0-3). Due to non-accessibility of the abdominal cavity in two patients
      (15.4%) and rapid clinical deterioration in six patients (46%), five patients
      underwent two or more PIPAC applications and were, therefore, eligible for
      histological analysis to assess carcinoma regression. Overall tumor regression of
      any degree was determined in 4/5 patients. An overall median survival of 85 days 
      (95% confidence interval(CI)=59.2-110.4 days) after the first PIPAC application
      was observed. No complications greater than Common Terminology Criteria of
      Adverse Events (v4.0) level 2 occurred. CONCLUSION: PIPAC can induce objective
      regression of systemic chemotherapy-resistant peritoneal metastasis of biliary
      tract cancer. However, due to a rapid clinical deterioration of the patients,
      almost two-thirds of the patients cannot undergo repetitive PIPAC courses.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Falkenstein, Thomas A
AU  - Falkenstein TA
AD  - Basic Research Laboratories of the Department of Surgery, St. Mary's Hospital,
      Ruhr University Bochum, Herne, Germany.
FAU - Gotze, Thorsten O
AU  - Gotze TO
AD  - Institute of Clinical Cancer Research, UCT-University Cancer Center Frankfurt,
      Hospital Nordwest, Frankfurt, Germany.
FAU - Ouaissi, Mehdi
AU  - Ouaissi M
AD  - Department of Digestive, Oncology, Endocrine and Liver Transplantation,
      Colorectal Surgery Unit, Trousseau Hospital, Tours, France.
FAU - Tempfer, Clemens B
AU  - Tempfer CB
AD  - Department of Obstetrics and Gynecology, St. Mary's Hospital, Ruhr University
      Bochum, Herne, Germany.
AD  - General Surgery and Therapy Center for Peritoneal Carcinomatosis, St. Mary's
      Hospital, Ruhr University Bochum, Herne, Germany.
FAU - Giger-Pabst, Urs
AU  - Giger-Pabst U
AD  - Basic Research Laboratories of the Department of Surgery, St. Mary's Hospital,
      Ruhr University Bochum, Herne, Germany [email protected]
AD  - General Surgery and Therapy Center for Peritoneal Carcinomatosis, St. Mary's
      Hospital, Ruhr University Bochum, Herne, Germany.
FAU - Demtroder, Cedric
AU  - Demtroder C
AD  - General Surgery and Therapy Center for Peritoneal Carcinomatosis, St. Mary's
      Hospital, Ruhr University Bochum, Herne, Germany.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
OTO - NOTNLM
OT  - PIPAC
OT  - biliary tract
OT  - cancer
OT  - gallbladder
OT  - peritoneal metastasis
OT  - tumor regression
EDAT- 2017/12/27 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/26 00:00 [received]
PHST- 2017/11/14 00:00 [revised]
PHST- 2017/11/16 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
AID - 38/1/373 [pii]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):373-378.